Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates


Posted on 2 February 2021 | Posted in Evolocumab


Trial CHOlesterol Lowering and Residual Risk in Type 2 Diabetes (CHORD) Identifier: NCT04369664

Aim To investigate why individuals with type 2 diabetes are at increased risk for heart disease and stroke. This study will investigate risk factors for heart disease and stroke, including platelet activity, inflammation, blood vessel wall function, and genetic information, in participants with type 2 diabetes and elevated cholesterol.
Study design Non-randomized open-label study

Patients will be assigned to atorvastatin up to 80 mg daily, evolocumab 140 mg every 2 weeks and ezetimibe 10 mg daily

A control group without type 2 diabetes will receive the same treatments.

Patients will be followed-up at 4 weeks.

Patients 150 with type 2 diabetes aged between 18 and 90 years with low-density lipoprotein cholesterol (LDL-C) >100mg/dL
Co-primary endpoints Change in platelet activity (measured by monocyte-platelet aggregates and light transmission aggregometry test) before and after cholesterol reduction from baseline to 4 weeks
Key results Ongoing
Author conclusion

Related content